Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
Budesonide (1) ·
Cefdinir (1) ·
Celecoxib (1) ·
Cephalexin (1) ·
Clindamycin (1) ·
Cyproheptadine (hydrochloride) (1) ·
Enalapril (and enalaprilat IV) (1) ·
Erythromycin (1) ·
Fexofenadine (1) ·
Indomethacin (1) ·
Lorazepam (1) ·
Penicillin V (phenoxymethylpenicillin) (1) ·
Phenazopyridine (1) ·
Torsemide (1) ·
Tramadol (1)
Allegra, Allegra Allergy 24 Hour, Mucinex Allergy (combo) — all now OTC in US (1) ·
Ativan (oral, injectable), Loreev XR (1) ·
Celebrex (oral capsules), Elyxyb (oral solution, for acute migraine) (1) ·
Cleocin (oral, IV); Clindesse, Cleocin (vaginal); Clindets, Cleocin T (topical) (1) ·
Demadex, Soaanz (1) ·
E.E.S., EryPed, Ery-Tab, PCE, Erythrocin (lactobionate IV); topical Erygel, Akne-Mycin; ophthalmic ointment (1) ·
Indocin (oral, IV, suppository), Tivorbex (low-dose), Indo-Lemmon (1) ·
Keflex, Daxbia, Panixine; mostly prescribed generically (1) ·
Omnicef (discontinued in US under brand); mostly generic (1) ·
Pen-V, Veetids (mostly generic) (1) ·
Periactin (US brand discontinued; generic widely available) (1) ·
Pulmicort (inhaled), Rhinocort (intranasal), Entocort EC and Uceris (enteric-coated oral for IBD), Symbicort (with formoterol) (1) ·
Pyridium (Rx), Azo Standard, AZO Urinary Pain Relief (OTC) (1) ·
Ultram (IR), Ultram ER, ConZip ER (1) ·
Vasotec, Vasotec IV, Epaned (1)
narrow-spectrum)]] (1) ·
potent non-selective)]] (1) ·
selective COX-2)]] (1) ·
weak μ-agonist with serotonin/norepinephrine reuptake inhibition)]] (1) ·
[[:Category:ACE_inhibitors|ACE inhibitor]] (1) ·
[[:Category:Analgesics|Analgesic]] (3) ·
[[:Category:Antibacterials|Antibacterial]] (2) ·
[[:Category:Antihistamines|Antihistamine]] (1) ·
[[:Category:Antihistamines|First-generation antihistamine]] (1) ·
[[:Category:Antihypertensives|Antihypertensive]] (1) ·
[[:Category:Anxiolytics|Anxiolytic]] (1) ·
[[:Category:Azo_dyes|Azo dye]] (1) ·
[[:Category:Benzodiazepines|Benzodiazepine]] (1) ·
[[:Category:Beta-lactam_antibiotics|β-lactam antibiotic]] (3) ·
[[:Category:Cephalosporins|Cephalosporin (first-generation)]] (1) ·
[[:Category:Cephalosporins|Cephalosporin (third-generation)]] (1) ·
[[:Category:Corticosteroids|Corticosteroid]] (1) ·
[[:Category:Glucocorticoids|Glucocorticoid]] (1) ·
[[:Category:H1_receptor_antagonists|Histamine H1 receptor antagonist (second-generation)]] (1) ·
[[:Category:Inhaled_corticosteroids|Inhaled corticosteroid (ICS)]] (1) ·
[[:Category:Lincosamides|Lincosamide antibiotic]] (1) ·
[[:Category:Loop_diuretics|Loop diuretic]] (1) ·
[[:Category:Macrolide_antibiotics|Macrolide antibiotic]] (1) ·
[[:Category:NSAIDs|Non-steroidal anti-inflammatory (NSAID (2) ·
[[:Category:Opioid analgesics|Opioid analgesic (atypical (1) ·
[[:Category:Orexigenics|Appetite-promoting medicine (orexigenic)]] (1) ·
[[:Category:Penicillins|Penicillin (natural (1) ·
[[:Category:Prokinetics|Prokinetic (off-label)]] (1) ·
[[:Category:Schedule IV controlled substances|Schedule IV controlled substance]] (2) ·
[[:Category:Serotonin antagonists|Serotonin 5-HT2 antagonist]] (1) ·
[[:Category:Urinary_analgesics|Urinary tract analgesic]] (1)
None (12) ·
'"`UNIQ--vote-00000017-QINU`"' Anticholinergic and sedating, with the standard first-generation antihistamine Beers-list concerns in elderly patients'"`UNIQ--ref-00000018-QINU`"'. (1) ·
'"`UNIQ--vote-00000B40-QINU`"' The TRANSFORM-HF trial (2023) found no all-cause mortality difference between torsemide and furosemide in heart failure, although torsemide remains pharmacologically preferred where furosemide oral absorption is unreliable'"`UNIQ--ref-00000B41-QINU`"'. (1) ·
'"`UNIQ--vote-00000CC9-QINU`"' Mostly excreted unchanged in feces and urine; P-glycoprotein substrate (the basis of the fruit-juice interaction). (1)
'"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"' (1) ·
'"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"' (1) ·
'"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"' (1) ·
'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (1) ·
'"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"' (1) ·
'"`UNIQ--vote-000004ED-QINU`"', '"`UNIQ--vote-000004EE-QINU`"', '"`UNIQ--vote-000004EF-QINU`"', '"`UNIQ--vote-000004F0-QINU`"', '"`UNIQ--vote-000004F1-QINU`"' (1) ·
'"`UNIQ--vote-0000099F-QINU`"', '"`UNIQ--vote-000009A0-QINU`"', '"`UNIQ--vote-000009A1-QINU`"', '"`UNIQ--vote-000009A2-QINU`"', '"`UNIQ--vote-000009A3-QINU`"', '"`UNIQ--vote-000009A4-QINU`"' (1) ·
'"`UNIQ--vote-000009DF-QINU`"', '"`UNIQ--vote-000009E0-QINU`"', '"`UNIQ--vote-000009E1-QINU`"', '"`UNIQ--vote-000009E2-QINU`"', '"`UNIQ--vote-000009E3-QINU`"' (1) ·
'"`UNIQ--vote-00000B42-QINU`"', '"`UNIQ--vote-00000B43-QINU`"', '"`UNIQ--vote-00000B44-QINU`"', '"`UNIQ--vote-00000B45-QINU`"' (1) ·
'"`UNIQ--vote-00000B81-QINU`"', '"`UNIQ--vote-00000B82-QINU`"', '"`UNIQ--vote-00000B83-QINU`"' (1) ·
'"`UNIQ--vote-00000CCA-QINU`"', '"`UNIQ--vote-00000CCB-QINU`"' (1) ·
'"`UNIQ--vote-00000D38-QINU`"', '"`UNIQ--vote-00000D39-QINU`"', '"`UNIQ--vote-00000D3A-QINU`"', '"`UNIQ--vote-00000D3B-QINU`"', '"`UNIQ--vote-00000D3C-QINU`"', '"`UNIQ--vote-00000D3D-QINU`"' (1) ·
'"`UNIQ--vote-00000E71-QINU`"', '"`UNIQ--vote-00000E72-QINU`"', '"`UNIQ--vote-00000E73-QINU`"', '"`UNIQ--vote-00000E74-QINU`"', '"`UNIQ--vote-00000E75-QINU`"' (1) ·
'"`UNIQ--vote-00000FB3-QINU`"', '''adjunctive only''' (does not treat the underlying infection) (1) ·
'"`UNIQ--vote-0000143C-QINU`"', '"`UNIQ--vote-0000143D-QINU`"', '"`UNIQ--vote-0000143E-QINU`"', '"`UNIQ--vote-0000143F-QINU`"', '"`UNIQ--vote-00001440-QINU`"', '"`UNIQ--vote-00001441-QINU`"' (1)
10-20 mg PO/IV once daily; titrate by clinical response. 1:1 IV to PO conversion (unlike furosemide's 1:2) (1) ·
100-200 mg PO TID after meals × no more than 2 days when used with concurrent antibiotic (1) ·
250-500 mg PO every 6-8 hours (1) ·
250-500 mg PO QID; 7.5-12.5 mg/kg IV q6h; topical and ophthalmic per formulation (1) ·
300 mg PO BID, or 600 mg PO once daily, ×5-10 days; pediatric 14 mg/kg/d (1) ·
5-10 mg PO once daily (2.5 mg if on diuretic or in heart failure); titrate to 10-20 mg BID for HFrEF (1) ·
500 mg PO every 6 hours, or 250 mg every 6 hours for mild infections (1) ·
60 mg PO BID or 180 mg PO once daily (1) ·
Acute gout: 50 mg PO TID until symptom relief, then taper; maximum 200 mg/day for 3-5 days. Rheumatoid arthritis / osteoarthritis: 25-50 mg PO BID-TID. Patent ductus arteriosus: 0.2 mg/kg IV, then 0.1-0.2 mg/kg every 12-24 hours for 2 doses (1) ·
Allergy: 4 mg PO TID. Serotonin syndrome: 12 mg loading dose PO or by nasogastric tube, then 2 mg every 2 hours until clinical improvement. Appetite stimulation: 2-4 mg PO TID-QID (1) ·
Anxiety: 0.5-1 mg PO BID-TID. Insomnia: 1-2 mg PO at bedtime. Status epilepticus: 4 mg IV (adult), repeat after 5-10 minutes if needed. Acute agitation: 1-2 mg IM (1) ·
ICS Pulmicort Flexhaler 180-360 mcg BID; intranasal Rhinocort 64 mcg/spray, 1-2 sprays/nostril daily; Entocort EC 9 mg PO daily for active Crohn's; Symbicort 80/4.5 or 160/4.5 mcg, 2 puffs BID (1) ·
IR: 25-50 mg PO every 4-6 hours as needed, titrate as tolerated. ER: 100 mg PO once daily, titrate by 100 mg every 5 days (1) ·
Oral 300-450 mg PO QID; IV 600-900 mg q8h; topical 1% solution/gel BID; vaginal 100 mg ovule × 3 days or 2% cream × 7 days (1) ·
Osteoarthritis: 200 mg PO once daily or 100 mg BID. Rheumatoid arthritis: 100-200 mg PO BID. Acute pain: 400 mg loading, then 200 mg every 12 hours (1)
2.5, 5, 10, 20 mg tablets; 1 mg/mL oral solution (Epaned); 1.25 mg/mL IV (enalaprilat) (1) ·
250 mg, 500 mg tablets; 125 mg/5 mL, 250 mg/5 mL suspension (1) ·
250 mg, 500 mg, 750 mg capsules; 250 mg/5 mL, 125 mg/5 mL suspension; tablets (1) ·
250, 500 mg base or stearate tablets; ER tablets; ethyl succinate 200 mg/5 mL suspension; 500 mg, 1 g IV (lactobionate); 2% topical solution/gel; 0.5% ophthalmic ointment (1) ·
30, 60, 180 mg tablets; 30 mg ODT; 6 mg/mL oral suspension; all OTC (1) ·
300 mg capsules; 125, 250 mg/5 mL suspension (1) ·
5, 10, 20, 100 mg tablets; 10 mg/mL IV (1) ·
75, 150, 300 mg capsules; 75 mg/5 mL solution; 150 mg/mL IV; 1% topical; 2% vaginal cream (1) ·
95 mg (OTC), 99.5 mg, 100 mg, 200 mg tablets (1) ·
Capsules 25, 50 mg; ER capsules 75 mg; oral suspension 25 mg/5 mL; suppositories 50 mg; injection 1 mg/vial (PDA closure) (1) ·
Capsules 50, 100, 200, 400 mg; Elyxyb oral solution 25 mg/mL (1) ·
IR tablets 50 mg; ER tablets 100, 200, 300 mg (Ultram ER, ConZip); oral solution 5 mg/mL; combination products with acetaminophen (Ultracet) (1) ·
Pulmicort Flexhaler DPI 90, 180 mcg/dose; Pulmicort Respules 0.25, 0.5, 1 mg/2 mL nebulized; Rhinocort intranasal 32 mcg/spray; Entocort EC 3 mg capsules; Uceris 9 mg ER tablets and rectal foam (1) ·
Tablets 0.5, 1, 2 mg; oral concentrate 2 mg/mL; injection 2 mg/mL and 4 mg/mL; Loreev XR capsules 1, 2, 3 mg (1) ·
Tablets 4 mg; oral syrup 2 mg/5 mL (1)
10 mg/day (anxiety, oral) (1) ·
180 mg/d (adults) (1) ·
2 g/d typical (1) ·
200 mg/d typical practical ceiling (1) ·
200 mg/day (typical adult oral) (1) ·
32 mg/day adult; weight-based pediatric ceiling (1) ·
4 g/d (1) ·
4 g/d (rarely tolerated due to GI effects) (1) ·
4.8 g/d (IV severe infection) (1) ·
40 mg/d (1) ·
400 mg/day (IR, adult); 300 mg/day (ER); 300 mg/day in elderly >75 years (1) ·
400 mg/day for chronic indications; higher for short-term acute pain (1) ·
600 mg/d (1) ·
ICS ~1280 mcg/d; intranasal 256 mcg/d; Entocort 9 mg/d standard (1) ·
Limit to 48 hours of use to avoid hemolysis and methemoglobinemia (1)
1-2 hours (1) ·
30-60 minutes (2) ·
30-60 minutes (IR) (1) ·
30-60 minutes (oral); 5 minutes (IV); 15-30 minutes (IM) (1) ·
30-60 minutes (oral); rapid relief in acute gout (1) ·
BP effect 1 hour; max at 4-6 hours (1) ·
Hours (5) ·
Inhaled: bronchial effect 1-2 weeks; oral GI effect 1-2 weeks (1) ·
PO 1 hour; IV 10 minutes (1) ·
Symptom relief within 30 minutes (1)
12-15 hours (intermediate); '''no active metabolites''' (key clinical feature)'"`UNIQ--ref-00000023-QINU`"' (1) ·
3-4 hours (similar between PO and IV due to high oral bioavailability)'"`UNIQ--ref-00000B46-QINU`"' (1) ·
4-5 hours'"`UNIQ--ref-00000026-QINU`"' (1) ·
8-16 hours'"`UNIQ--ref-0000001E-QINU`"' (1) ·
Tramadol 6-7 hours; M1 active metabolite 7-9 hours'"`UNIQ--ref-0000001D-QINU`"' (1) ·
~1 hour'"`UNIQ--ref-000004F2-QINU`"' (1) ·
~1.5-2 hours'"`UNIQ--ref-00000D3E-QINU`"' (1) ·
~1.7 hours'"`UNIQ--ref-000009E4-QINU`"' (1) ·
~11 hours (enalaprilat, the active metabolite)'"`UNIQ--ref-00000B84-QINU`"' (1) ·
~11 hours'"`UNIQ--ref-00000029-QINU`"' (1) ·
~14 hours'"`UNIQ--ref-00000CCC-QINU`"' (1) ·
~2-3.6 hours (plasma)'"`UNIQ--ref-000009A5-QINU`"' (1) ·
~2.5-3 hours'"`UNIQ--ref-00001442-QINU`"' (1) ·
~30-60 minutes'"`UNIQ--ref-00000E76-QINU`"' (1) ·
~7-10 hours (variable; longer in renal impairment)'"`UNIQ--ref-00000FB4-QINU`"' (1)
16-21% capsule, 25% suspension (oral; iron and antacids reduce absorption substantially)'"`UNIQ--ref-000009E5-QINU`"' (1) ·
90% (oral; food delays but does not reduce absorption)'"`UNIQ--ref-000004F3-QINU`"' (1) ·
High (oral)'"`UNIQ--ref-00000FB5-QINU`"' (1) ·
~100% (oral)'"`UNIQ--ref-00000027-QINU`"' (1) ·
~30-65% (oral; acid-labile, hence enteric-coated formulations; food affects absorption variably)'"`UNIQ--ref-00000D3F-QINU`"' (1) ·
~33% (oral; fruit juices including grapefruit, orange, and apple reduce absorption substantially via OATP1A2 inhibition — distinctive interaction not seen with most other H1s)'"`UNIQ--ref-00000CCD-QINU`"' (1) ·
~6-13% inhaled lung deposition; ~10% oral (Entocort EC; extensive first-pass via CYP3A4 — this is the basis of the favorable hepatic-targeted local-effect profile in IBD)'"`UNIQ--ref-000009A6-QINU`"' (1) ·
~60% (oral; food does not affect absorption)'"`UNIQ--ref-00000B85-QINU`"' (1) ·
~60% (oral; phenoxymethyl modification makes it acid-stable, unlike penicillin G which is destroyed by gastric acid)'"`UNIQ--ref-00000E77-QINU`"' (1) ·
~75% (IR, rises with multi-dose administration due to saturable first-pass)'"`UNIQ--ref-0000001E-QINU`"' (1) ·
~80% (oral; predictable absorption — a substantive practical advantage over furosemide whose oral absorption is 10-100% variable)'"`UNIQ--ref-00000B47-QINU`"' (1) ·
~90% (oral)'"`UNIQ--ref-00000024-QINU`"' (1) ·
~90% (oral)'"`UNIQ--ref-00001443-QINU`"' (1) ·
~95% (oral)'"`UNIQ--ref-0000001F-QINU`"' (1) ·
~99% (oral)'"`UNIQ--ref-0000002A-QINU`"' (1)
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension. Stop on detection'"`UNIQ--ref-00000B86-QINU`"' (1) ·
Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)'"`UNIQ--ref-0000002B-QINU`"' (1) ·
Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning; contraindicated from 30 weeks (risk of premature ductus arteriosus closure, which is paradoxically the basis of the neonatal PDA-closure indication)'"`UNIQ--ref-00000028-QINU`"' (1) ·
Avoid where possible; class concerns as for other loop diuretics.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Chronic third-trimester exposure produces neonatal opioid withdrawal syndrome and respiratory depression at delivery.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; commonly used in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; loratadine and cetirizine have more pregnancy data and are typically preferred.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; widely used.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Limited data; not first-line in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; older agent with substantial use experience.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Long the preferred ICS in pregnancy (Pulmicort) due to the most pregnancy data among the class.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Some signal for cleft lip/palate with first-trimester exposure (debated); neonatal sedation and withdrawal with third-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
OTC (intranasal Rhinocort Allergy) and [[USLegal:Prescription only|Rx-only]] (other forms) in US (1) ·
OTC (lower doses) and [[USLegal:Prescription only|Rx-only]] (higher doses) in US (1) ·
OTC (ophthalmic ointment) and [[USLegal:Prescription only|Rx-only]] (other forms) in US (1) ·
OTC in US (1) ·
[[USLegal:Prescription only|Rx-only]] in US (8) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for Clostridioides difficile colitis (one of the most C. difficile-inducing antibiotic classes)'"`UNIQ--ref-00001444-QINU`"' (1) ·
[[USLegal:Schedule IV|Schedule IV controlled substance]] in US (federally scheduled 2014); some states schedule higher'"`UNIQ--ref-0000001F-QINU`"' (1) ·
[[USLegal:Schedule IV|Schedule IV controlled substance]] in US. Carries the benzodiazepine class '''Boxed Warning''' for risk of fatal respiratory depression, coma, and death when combined with opioids'"`UNIQ--ref-00000025-QINU`"' (1)
Showing below up to 15 results in range #1 to #15.


